Was bedeutet, wohin "wenden sie sich denn?

Ket(oconazole) hat aber systemisch sehr heftige NW, weshalb es oral auch verboten ist.

Zur RU habe ich schon alles gesagt. Wenn dir das risikoloser erscheint als FIN...was soll ich sagen. Jeder muss seine Entscheidung alleine treffen. Topisch kann eben auch systemisch gehen.

wurde doch oral hier noch NIE empfohlen

1.Für mich ist es logisch das wenn DHT im Alter abnimmt, die NWs die durch zusätzliche Hemmung von DHT entstehen prägnanter ausfallen, wenn grunsätzlich schon weniger da ist. Man wird älter kleinere Libido.

2.Ich meinte RU ist interessant, ich wüßte gerne mehr darüber. Habe noch nichts von NWs gelesen in keinem Bericht. Aber hingegen bei Fin jede Menge über Libido und Ähnlichem...

Bei ell cranell sind die Erfolgsberichte sehr rar / nicht vorhanden, ähnlich gestaltet es sich bei Finasterid topisch. Die eventuelle Wirkung kommt daher, dass es trotz topischen Anwendung ins Blut geht. Da wäre oral effektiver und die Nebenwirkungen sind die gleichen.

Minoxidil ist topisch super, jedoch alleine wirst du langfristig keinen Erfolg damit haben.

Materials and Methods

Initial dosing studies were designed to establish the most effective topical concentration of finasteride with respect to serum DHT 5mg Proscar tablets were crushed to prepare the appropriate concentration suitable for topical dosing studies.

Males with genetic hair loss were selected on a named patient basis, and all gave their informed consent. Following a baseline blood test and medical examination, hair variables were assessed with the Unit Area Trichogram (a method with proven reproducibility) basely and, from the same sites, 12 months later. All blood tests were performed before 11 am following a 12 hr fast, with follow-up blood tests and medical examinations after 1, 4, and 12 months of therapy.

Results
Hormonal changes during dosing studies

The dosing study data are presented in Table 1 and Table 2. The results show that a twice daily application of 0.05% finasteride solution (2 x 2 ml) significantly lowers the serum DHT concentration, with only a marginal increase in DHT suppression being observed when the concentration was increased from 0.05% to 0.075% (data not presented).

Table 1.
Dosing data (mean, n=2) for topical 0.01% finasteride (2 x 2 ml daily) over a four week duration.

........................................ Week 0 ...... Week 1 ............. Week 4 ..... % Change
Testosterone (nmol/L) ..... 25.0 ........... 31.0 .................. 25.0 ............. 0%
DHT (nmol/L) ..................... 2.9 ............. 1.7 .................... 1.7 ............. -31%

Table 2.
Dosing data (mean +/- sd, n=9) for topical 0.05% finasteride (2 x 2 ml daily) over a 4 week duration

........................................ Week 0 ...... Week 4 ....... % Change ........ (paired t-test)
Testosterone (nmol/L) ...... 20.2 ......... 19.4 ............... -4% ................ NS
DHT (nmol/L) ..................... 1.8 ........... 1.1 ................ -39% ............... p<0.003

Hormonal and hair changes during topical 0.05% finasteride therapy
(Table 3)

During the treatment period significant suppression of the serum DHT was achieved in all individuals, with each remaining below the lower limit of normal (1.3 to 2.5 nmol/L) throughout treatment. In addition, no significant reduction in circulating serum testosterone or oestradiol concentration was found. The mean values obtained for total hair density (hair per cm^2) and non-vellus hair density are also presented. A vellus hair was defined as a hair less than or equal to 40 um in diameter, less than or equal to 30 mm in length.

Table 3.
Mean hair densities and hormonal values from 5 subjects treated with topical 0.05% finasteride for 12 months

Time (months) ........................ 0 ................. 12 ....... Significance ...... Normal Range
Total hair per cm^2 .............. 256 ............. 248 ............ NS ................ (256 - 359)
Non-vellus hair per cm^2 ..... 174 ............. 158 ............ NS ................ (232 - 325)
Testosterone (nmol/L) .......... 15.0 ............ 14.0 ........... NS ............... (10.0 - 35.0)
DHT (nmol/L) ......................... 1.42 ............ 0.85 ......... p<0.01 ........... (1.3 - 2.5)

Objective: The effects on scalp and serum dihydrotestosterone (DHT) of different doses of a novel topical solution of 0.25% finasteride (P-3074), a type 2 5α-reductase, were investigated in men with androgenetic alopecia. Methods: Two randomized, parallel-group studies were conducted. Study I: 18 men received 1 mL (2.275 mg) P-3074, applied to the scalp once a day (o.d.) or twice a day (b.i.d), or 1 mg oral tablet o.d. for 1 week. Study II: 32 men received P-3074 at the dose of 100 (0.2275 mg), 200 (0.455 mg), 300 (0.6285 mg), or 400 (0.91 mg) μL or the vehicle o.d. for 1 week. Scalp and serum DHT and serum testosterone were evaluated at baseline and treatment end. Results: Change from baseline in scalp DHT was -70% for P-3074 o.d. and approx. -50% for P-3074 b.i.d. and the tablet. Serum DHT decreased by 60 - 70%. The doses of 100 and 200 μL P-3074 resulted in a -47/-52% scalp DHT reduction, similar to the 300 and 400 μL doses (i.e., -37/-54%). A -5.6% inhibition was observed for the vehicle. Serum DHT was reduced by only -24/-26% with 100 and 200 μL P-3074 and by -44/-48% with 300 and 400 μL P-3074. No relevant changes occurred for serum testosterone.


Conclusions: The novel finasteride 0.25% solution applied o.d. at the doses of 100 and 200 μL results in an appropriate inhibition of scalp DHT potentially minimizing the untoward sexual side-effects linked to a systemic DHT reduction.



https://www.researchgate.net/public...one_in_healthy_men_with_androgenetic_alopecia

Abbreviation: J Eur Acad Dermatol Venereol
Imprint Name(s):
Publication: Oxford : Wiley-Blackwell
Original Publication: Amsterdam ; New York : Elsevier Science Publishers, c1992-
Abstract:
Background: The synergism of combined use between oral finasteride and topical minoxidil has been established in treating androgenetic alopecia among men. However, the concern regarding adverse effects of finasteride use has been rising.
Objective: To compare the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in men with androgenetic alopecia.
Methods: Forty men aged 18 to 60 years with androgenetic alopecia were randomized to 24 weeks of treatment with a finasteride/minoxidil or minoxidil solution twice daily. Primary efficacy endpoint was the change from baseline in hair density and hair diameter at week 24. Secondary endpoints included global photographic assessment by treatment-blinded investigators and subjects. Changes in plasma dihydrotestosterone levels and adverse events were recorded.
Results: At week 24, the combined solution of finasteride and minoxidil was significantly superior to minoxidil alone in improvements of hair density, hair diameter and global photographic assessment (all P < 0.05). About 90% of patients treated with the combined solution experienced moderate to marked improvement.

The combined solution also had minimal effect on plasma dihydrotestosterone levels, approximately 5% reduction. There were also no systemic adverse events reported by patients in both groups.


Conclusion: Treatment with topical solution of 0.25% finasteride admixed with 3% minoxidil was significantly superior to 3% minoxidil solution for promoting hair growth in male androgenetic alopecia, and well tolerated. This article is protected by copyright. All rights reserved.
(This article is protected by copyright. All rights reserved.)
Contributed Indexing:
Keywords: androgenetic alopecia; finasteride; male pattern hair loss; topical finasteride; topical minoxidil
Entry Date(s):
Date Created: 20180705 Latest Revision: 20180704
Update Code:
20180705
DOI:
10.1111/jdv.15171

Also ich benutze seit 8 Wochen Fin topisch und mein Haarstatus hat sich seitdem stark verschlechtert. Besonders die Front ist massiv undichter geworden

Wenn du es ausprobierst mach nicht den gleichen Fehler wie ich und fang nur an einer kleinen Stelle an